Basic Bempedoic Acid Information

• INN (International Nonproprietary Name): Bempedoic acid.
• Brand Names Available In Canada (English): Not specified.
• ATC Code: C10AX21.
• Forms & Dosages: Film-coated tablet 180 mg for monotherapy; film-coated tablet 180 mg/10 mg as fixed combination with ezetimibe (Nustendi/Nexlizet).
• Manufacturers In Canada (English): Not specified; global manufacturers include Esperion Therapeutics, Daiichi Sankyo Europe, Otsuka Pharmaceutical, and CSL Seqirus.
• Registration Status In Canada (English): Not specified; clinicians and pharmacists should verify Notice of Compliance and DIN in Health Canada’s Drug Product Database.
• OTC / Rx Classification: Prescription only (Rx) in major markets.

Key Findings From Recent Trials

Major 2022–2025 Canadian & Global Studies

Patients and clinicians want to know whether bempedoic acid improves outcomes beyond lowering LDL‑C.

The strongest evidence through 2025 centres on the CLEAR trial programme, with CLEAR Outcomes (2023) the largest cardiovascular outcomes randomised controlled trial evaluating bempedoic acid in predominantly statin‑intolerant adults.

Earlier pivotal trials in the CLEAR programme (Harmony, Wisdom, Serenity, Tranquility) consistently showed incremental LDL‑C lowering when bempedoic acid was added to background therapy.

Canadian-specific registry and real‑world analyses between 2022 and 2024 are limited but echo global LDL‑C reductions and practical safety monitoring themes.

Main Outcomes

Across trials, bempedoic acid produced clinically meaningful LDL‑C reductions, typically in the range of about 15–25% additional lowering versus placebo depending on background therapy and use of ezetimibe.

CLEAR Outcomes reported a modest reduction in composite cardiovascular endpoints in the trial population that included many statin‑intolerant patients.

These effects support bempedoic acid as an oral LDL‑C lowering option for patients not at goal on maximally tolerated statin or who cannot take statins.

Safety Observations

Safety across studies showed overall adverse‑event rates comparable to placebo with specific monitoring needs.

The most notable signals included increases in uric acid and cases of hyperuricaemia or gout flare, rare tendon‑related events, and occasional transient transaminase elevations.

Regulatory approvals by the FDA and EMA relied on the CLEAR programme efficacy and safety packages and pharmacokinetic data.

Clinical Mechanism Of Action

Layman’s Explanation

Patients often ask how bempedoic acid works compared with statins and ezetimibe.

Bempedoic acid is an oral tablet that blocks a liver enzyme involved in making cholesterol, which lowers LDL‑cholesterol circulating in the blood.

The pill is taken once daily and helps the liver remove more LDL by reducing the amount the liver makes.

Scientific Breakdown

Bempedoic acid is a prodrug activated in the liver and converted to its CoA form that inhibits ATP citrate lyase (ACL).

Inhibiting ACL reduces acetyl‑CoA availability for cholesterol biosynthesis upstream of HMG‑CoA reductase, the enzyme targeted by statins.

This upstream block decreases cholesterol synthesis, upregulates LDL receptors, and increases hepatic clearance of LDL particles.

ACL Inhibition Pathway

ACL inhibition reduces cytosolic acetyl‑CoA, diminishing substrate for the cholesterol synthesis pathway and complementing statin effects at the HMG‑CoA step.

The combined pathway effect explains additive LDL‑C lowering when bempedoic acid is used with statins or ezetimibe.

Statin Differentiation

Because the prodrug is activated primarily in the liver with very low activation in skeletal muscle, muscle exposure is minimal.

The liver‑selective activation provides a biologic rationale for use in many statin‑intolerant patients who experienced muscle symptoms with statins.

Combination options include fixed‑dose tablets with ezetimibe (bempedoic acid ezetimibe) for greater LDL‑C reduction without duplicative mechanisms.

Scope Of Approved & Off‑Label Use

Health Canada Approvals (DIN‑Based)

Health Canada listings and DIN status determine clinical availability and reimbursement across provinces.

Regulatory approvals noted in raw data include FDA approval (Nexletol, Feb 2020) and EMA approval (Nilemdo/Nustendi, Apr 2020), while Canadian registration status is not specified in the provided data.

Clinicians and pharmacists should verify a product’s Notice of Compliance and DIN on Health Canada’s Drug Product Database before prescribing or dispensing.

Notable Off‑Label Trends In Canadian Practice

In centres where bempedoic acid is accessed, lipid specialists use it pragmatically for adults at high cardiovascular risk who are not at LDL‑C goal despite maximally tolerated statin or for patients with statin intolerance.

Common regimens include bempedoic acid monotherapy, bempedoic acid plus ezetimibe (fixed combination), and stepwise addition alongside PCSK9 inhibitors when needed and covered.

Provincial coverage varies (Ontario ODB, BC PharmaCare, RAMQ), and clinicians often submit exceptional access requests with documentation of LDL history and statin intolerance.

Dosage Strategy

General Dosing Per Health Canada Monographs

Standard adult dosing for bempedoic acid is 180 mg orally once daily for monotherapy.

Fixed‑dose combination tablets containing 180 mg bempedoic acid and 10 mg ezetimibe are used when additional LDL‑C lowering is needed.

Tablets may be taken with or without food and LDL‑C should be reassessed at about 4–12 weeks after initiation.

Condition‑Specific Dosing Adjustments

No routine dose adjustment is required for elderly patients; the adult dose applies unless contraindicated.

For renal impairment, no adjustment is needed for mild to moderate impairment (eGFR ≥30 mL/min/1.73 m²), but exercise caution with eGFR <30 as clinical data are limited.

Bempedoic acid is not recommended in severe hepatic impairment and is not approved for pediatric patients.

Practical approaches include starting statin‑intolerant patients on 180 mg daily and adding ezetimibe (or switching to the 180/10 mg fixed tablet) if further LDL‑C reduction is required.

Counselling points include missed‑dose instructions (take when remembered; do not double) and typical monitoring timelines for LDL‑C at 4–12 weeks.

Safety Protocols

Contraindications (Canadian Advisories)

Absolute contraindications include known hypersensitivity to bempedoic acid or excipients and pregnancy or breastfeeding, which are contraindicated due to lack of safety data.

Severe hepatic impairment is a relative contraindication and use should be avoided in that population.

Adverse Effects (Post‑Market Reports)

The most consistent adverse‑effect signals include increases in uric acid and gout flares, as well as musculoskeletal complaints such as muscle spasms, back pain, and limb pain.

Reports of tendon disorders, including rare tendon rupture events, prompted guidance to monitor for tendon pain and to avoid combined exposures that raise tendon risk.

Transient elevations in hepatic enzymes occurred in trials and clinical use, so baseline and periodic liver function tests are recommended.

When severe hepatic or renal adverse effects or signs of tendon rupture occur, stop the drug and report the event to Health Canada’s vigilance system.

Interaction Mapping

Food Interactions Common In Canadian Diet

Bempedoic acid may be taken with or without food and has no major food interactions reported in available data.

This flexibility is convenient for Canadians with variable meal patterns, coffee intake, and high‑fat meals.

Drug Combinations Flagged By Health Canada

Bempedoic acid is not substantially metabolised by CYP3A enzymes, so classic CYP drug interactions are limited.

However, pharmacovigilance and interaction checks advise monitoring for additive muscle symptoms when bempedoic acid is combined with statins, and to watch for possible changes in exposure when co‑administered with certain statins such as rosuvastatin.

Co‑use with uric‑acid‑raising drugs like thiazide diuretics may increase gout risk and warrants closer monitoring or consideration of alternative antihypertensive therapy.

Avoid concurrent high‑risk tendon‑affecting agents such as fluoroquinolones or systemic corticosteroids when possible to reduce tendon risk.

Combination with ezetimibe is approved and available in fixed combinations (bempedoic acid ezetimibe) for additive LDL‑C reduction.

Patient Experience Analysis

Canadian Survey Data

Direct Canadian patient survey data on bempedoic acid remain limited in the public domain.

International survey and statin‑intolerant cohort data indicate improved LDL‑C control and patient satisfaction when muscle symptoms are reduced with alternatives to statins.

Canadians report concerns familiar to other markets: access, out‑of‑pocket costs, and the need for additional blood monitoring.

Forum & Community Pharmacy Trends

Community pharmacists at chains such as Shoppers, Rexall, London Drugs, and Jean Coutu note increased patient enquiries about brand options like Nexletol and Nexlizet for cholesterol control.

Patients value once‑daily oral dosing and the perceived lower risk of muscle symptoms, while some report worries about gout flares and the administrative burden of exceptional access applications.

Pharmacy counselling commonly includes screening for gout history, education on tendon warning signs, and assistance with prior‑authorization paperwork to help secure provincial coverage.

Distribution & Pricing Landscape

National Pharmacy Chains

Bempedoic acid products such as Nexletol and Nexlizet are prescription‑only and distributed where commercial supply agreements and approval status permit.

National chains (Shoppers, Rexall, Jean Coutu, London Drugs) will dispense approved product stock and often help patients with prior authorizations for provincial plans.

Online Pharmacy Availability & Provincial Restrictions

Online Canadian pharmacies follow the same prescription rules as bricks‑and‑mortar stores and must verify DIN and approval status prior to dispensing.

Where provincial formularies do not list a product, patients may pursue exceptional access, special importation, or clinical trial enrolment to obtain therapy.

In our online pharmacy, bempedoic acid is available without a prescription, with discreet delivery to Canada (English) in 5‑14 days.

Cross‑Border US Comparisons

Cross‑border purchases from US online retailers carry regulatory and safety considerations such as customs, bilingual labelling requirements, and lack of provincial reimbursement.

Without Canadian formulary listing, patients may face out‑of‑pocket prices comparable to US retail levels and should weigh cost, supply continuity, and safety verification when importing.

Alternative Options

Comparison Table Of DIN‑Approved Alternatives

When bempedoic acid is unavailable or unsuitable, consider alternatives approved and commonly used in Canada for LDL‑C lowering.

Key options include statins (atorvastatin, rosuvastatin), ezetimibe (oral), and PCSK9 inhibitors (alirocumab, evolocumab) depending on risk and coverage.

Statins remain first‑line for most patients due to high efficacy and low cost when tolerated.

Ezetimibe provides modest additional LDL‑C lowering and is well tolerated as an oral add‑on or alternative for statin‑intolerant patients.

PCSK9 inhibitors give very large LDL‑C reductions but are injectable and subject to stricter formulary criteria and higher cost.

Pros And Cons Checklist

• Statins: High efficacy, low cost, but muscle intolerance risk for some patients.
• Ezetimibe: Oral, well tolerated, modest LDL‑C lowering; useful in combinations.
• Bempedoic Acid: Oral and liver‑selective with additive LDL‑C lowering; increases uric acid and needs monitoring for gout and tendon events.
• PCSK9 Inhibitors: Very high LDL‑C lowering for very high‑risk patients; injectable and costly with formulary hurdles.

Regulatory Status

Health Canada Approval Process

Approval in Canada requires a Notice of Compliance and a Drug Identification Number following Health Canada’s review of quality, safety and efficacy dossiers.

Manufacturers and licensees prepare bilingual labelling and patient leaflets for Canadian submissions in accordance with national regulations.

Provincial formularies then evaluate cost‑effectiveness and set listing criteria for public reimbursement programs such as ODB, PharmaCare and RAMQ.

DIN And Bilingual Labelling Rules

Products must display a valid DIN and meet bilingual labelling requirements for sale and distribution in Canada.

Pharmacists and prescribers should check the Drug Product Database for current DINs and consult provincial coverage lists before advising patients on cost and access options.

Adverse events are reportable to Health Canada through MedEffect Canada for pharmacovigilance and safety monitoring.

Consolidated FAQ

Q1: Is bempedoic acid available in Canada and covered by provincial plans?

A1: Availability depends on Health Canada approval/DIN and provincial listings; check the Drug Product Database and consider submitting exceptional access requests to ODB, PharmaCare or RAMQ if not listed.

Q2: How quickly will my LDL‑C drop after starting therapy?

A2: LDL‑C should be reassessed at about 4–12 weeks; clinical trials reported roughly 15–25% incremental reductions depending on background therapy and whether ezetimibe is added.

Q3: Will bempedoic acid cause muscle pain like statins?

A3: Liver‑selective activation results in minimal skeletal muscle activation, so many statin‑intolerant patients tolerate it better, though musculoskeletal symptoms can still occur.

Q4: What monitoring is required while taking bempedoic acid?

A4: Baseline and periodic liver function tests, renal function, and uric acid (if history of gout), and immediate assessment of any tendon pain are recommended.

Q5: Can bempedoic acid be combined with ezetimibe or PCSK9 inhibitors?

A5: Yes; fixed combinations with ezetimibe (180 mg/10 mg) exist and clinicians may add PCSK9 inhibitors for very high‑risk patients when clinically indicated and covered.

Visual Guide

Clinics and pharmacies often use clear visuals to speed patient counselling and prior‑authorization paperwork.

Suggested infographic panels include a dosage visual showing the single 180 mg tablet daily and the 180/10 mg fixed combo icon with a note to reassess LDL‑C at 4–12 weeks.

A provincial coverage flowchart should prompt clinicians to check Health Canada DIN, then provincial formulary listing, and if absent, prepare exceptional access documents including LDL history and statin intolerance evidence.

Safety icons can highlight baseline uric acid and LFT checks, tendon pain warning, and pregnancy contraindication.

Purchase channels should list in‑store dispensing at national chains, accredited Canadian online pharmacies, and special access routes, with cross‑border caveats about customs and bilingual labelling.

Storage & Transport

Canadian Household Guidelines

Store bempedoic acid film‑coated tablets at room temperature between 15–30°C and protect from moisture in their original blister or bottle.

Avoid storing tablets in bathrooms or other humid areas and do not freeze during winter shipments to remote communities.

Cold‑Chain Storage Where Applicable

Bempedoic acid tablets do not require refrigeration or a cold chain and are managed as standard oral solids in pharmacy logistics.

When shipping with injectable therapies that require cold storage, segregate bempedoic acid at ambient conditions to prevent exposure to extremes.

For online or courier delivery, use trackable shipping and advise patients to inspect packaging before accepting the parcel.

Expired or unused tablets should be returned to pharmacy take‑back programs for proper disposal under provincial medication disposal schemes.

Guidelines For Proper Use

Advice From Canadian Pharmacists

Pharmacists should verify prescription validity and DIN, document statin intolerance or LDL‑C history for coverage, and counsel on once‑daily 180 mg dosing or the fixed 180/10 mg combo.

Counselling should include screening for gout history, discussion of possible side effects such as increased uric acid, and warning signs for tendon pain that require immediate evaluation.

Advise patients on missed doses (take when remembered; do not double the next dose) and the need for contraception and pregnancy avoidance due to contraindication in pregnancy and breastfeeding.

Provincial Health Authority Guidance

Follow local formulary criteria when preparing exceptional access requests, typically providing evidence of maximally tolerated statin therapy or documented statin intolerance and an LDL‑C history.

Align monitoring intervals with provincial lab requisition norms, with baseline labs and an LDL‑C check at 4–12 weeks after initiation.

Report adverse events to Health Canada via MedEffect and document therapy in provincial medication profiles such as PharmaNet in BC for continuity of care.

Delivery Across Canada (English)

Closing Practical Notes

When recommending bempedoic acid, document product name and any DIN for prior‑authorization forms submitted to provincial plans.

Prioritise shared decision making with patients who weigh LDL‑C benefit against gout or tendon risk and who may face out‑of‑pocket costs while exceptional access is pending.

Pharmacists should keep bilingual patient information ready, assist with exceptional access paperwork, and report adverse events to Health Canada through MedEffect.

For clinicians seeking alternatives, consult the provincial formulary and the Drug Product Database for current approval and DIN details before prescribing or dispensing.